Project Updates
Alnylam, Massachusetts
Credit: Alnylam
Project name: Alnylam’s Manufacturing Facility, US
Location: Norton, Massachusetts
Project type: Biopharmaceutical manufacturing facility
Start of Construction: 2016
Investment: $200m
Alnylam Pharmaceuticals, has built a new drug manufacturing and cGMP warehouse facility in Norton, Massachusetts, US. The facility produces the company’s RNA interference (RNAi) therapeutics to fulfil global clinical and commercial demand.
Upperton, Nottingham
Credit: Upperton Pharma Solutions
Project name: Upperton’s Pharmaceutical Development and GMP Manufacturing Facility, UK
Location: Nottingham, UK
Project type: Development and GMP manufacturing facility
Area: 50,000ft2
Estimated Investment: £15m ($18.7m)
Upperton Pharma Solutions, a CDMO is building a new development and GMP headquarters in Nottingham, to support early formulation development and early-to-late-stage clinical trials product supplies.
Lonza, Visp
Credit: Lonza
Project name: Lonza’s Bioconjugation Facility Expansion, Visp
Location: Visp, Switzerland
Project type: Bioconjugation facility expansion
Announced: December 2020
Owner: Lonza
Lonza completed the expansion of its bioconjugation facility in Visp, Switzerland in February 2023. The expansion improved the facility’s bioconjugation capabilities and helped in meeting the increased demand for bioconjugates.
